EBS 8-K 2026-11-02

Emergent BioSolutions Inc. (EBS) 8-K dated 2026-11-02 — accession 0001367644-26-000110.

Emergent BioSolutions Inc. (EBS) is a drug manufacturers - specialty & generic company listed on US.

Emergent BioSolutions Inc. filed a 8-K on 2026-11-02. Accession 0001367644-26-000110.

This 8-K covers: Results of operations (Item 2.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported EBS revenue for 2025-12-31 was $742.9M. Net income was $52.6M. Revenue was down 28.8% from 2024-12-31 to 2025-12-31. EBS currently screens at market cap $416.4M.

Not investment advice. The EBS SEC hub lists recent forms. The stock page is the research view.